XML 71 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
Divestitures and Sale of License Rights (Narrative) (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 30, 2016
Jul. 07, 2016
Dec. 31, 2016
Sep. 30, 2016
Aug. 31, 2016
Dec. 31, 2014
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Loss on divestitures             $ 268 $ (3,405) $ (496) $ 55,453 $ 0 $ 51,820 $ 0
Comet Brand                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Proceeds from Early Buyout           $ 10,000              
Royalty revenue           1,000              
Proceeds from sale of license rights         $ 11,000 $ 10,000              
Gain on sale of asset         1,200                
Indefinite-lived intangibles, reductions         $ 9,000                
Disposal group, disposed of by sale, not discontinued operations | Pediacare, New Skin and Fiber Choice | Cough and Cold, Dermatologicals, and Gastrointestinal products group | North American OTC Healthcare                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Consideration, excluding costs of inventory   $ 40,000                      
Loss on divestitures                       $ 56,200  
Indefinite-lived intangibles, reductions   $ 37,200                      
Disposal group, disposed of by sale, not discontinued operations | Dermoplast | Cough and Cold, Dermatologicals, and Gastrointestinal products group | North American OTC Healthcare                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Deposit for agreement to purchase       $ 1,250                  
Indefinite-lived intangibles, reductions $ 31,000                        
Disposal group, disposed of by sale, not discontinued operations | E.P.T. and Dermoplast | Cough and Cold, Dermatologicals, and Gastrointestinal products group | North American OTC Healthcare                          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                          
Total purchase price received     $ 59,600         $ 59,600          
Pre-tax net gain on divestitures     $ 3,900